European Commission approves Ronapreve to treat Covid-19
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
Evidence also shows better immune response to virus among users of spray
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The preregistrations are aimed at registering both healthy children and those with comorbidities whereas preference will be given for children with comorbidities
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Subscribe To Our Newsletter & Stay Updated